Clinical trial
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
Abstract
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticlePsilocybin
Association of Psilocybin Use in Adolescents with Major Depressive Episode
ArticlePsilocybin
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
ArticlePsilocybin